Background Guidelines do not recommend that cancer outpatients receive
thromboprophylaxis unless at high venous thromboembolism (VTE) risk, with the Khorana …

Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer
varies and prophylaxis is inconsistently used. A previously validated tool (Khorana …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Background Current guidelines recommend all cancer inpatients receive pharmacologic
VTE prophylaxis in the absence of contraindications. This is extrapolated from trials showing …

6598 Background: Quality panels and regulators have focused on inpatient venous
thromboembolism (VTE) as a priority preventable illness. VTE is very prevalent in cancer but …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

BACKGROUND: Recent studies suggest that thromboprophylaxis is beneficial in preventing
venous thromboembolism (VTE) in cancer outpatients, but this is not widely adopted …

BACKGROUND: Venous thromboembolism is a well-known complication of malignancy.
The Khorana Risk Score (KRS) utilizes the type of cancer, blood counts, and body mass …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

Abstract Background The Khorana Score is a validated risk score for predicting 6‐month
incidence of cancer‐associated venous thromboembolism (CAT) among patients starting …